Dario A. Vignali, PhD
- PhD, Immunology of Infectious Diseases, University of London, 1988
- BSc, Immunology and Medical Microbiology, North East London Polytechnic, 1985
Professor and Vice Chair, Department of Immunology
Frank Dixon Chair in Cancer Immunology
Co-Leader, Cancer Immunology and Immunotherapy Program
Co-Director, Tumor Microenvironment Center
Scientific Director of Fondazione Ri.MED
Director, Cancer Immunology Training Program
Member, Graduate Program in Microbiology and Immunology (PMI)
Dr. Vignali began his academic career at St. Jude Children’s Research Hospital where he became Vice Chair and Full Professor. In 2014, Dr. Vignali moved to the University of Pittsburgh, School of Medicine to become Vice Chair and Professor of Immunology, Co-Leader of the Cancer Immunology Program and Co-Director of the Tumor Microenvironment Center.
Dr. Vignali’s research focuses on gaining a better understanding of the inhibitory mechanisms, including inhibitory receptors and regulatory T cells, that limit anti-tumor immunity in cancer patients. I also have discovery-based programs aimed at identifying novel targets for therapeutic intervention. I am also working with UPCI scientists and clinicians to facilitate the translation of novel therapeutic modalities with a focus on immunologically impacted solid tumors (primarily head and neck, melanoma, lung, pancreatic cancer). My UPCI leadership efforts are directed toward providing a bridge between basic and transitional cancer immunology. Lastly, I also work extensively with large and start-up biopharmaceutical companies to bring novel therapeutics to the clinic.
Dr. Vignali has served as a member of: the American Association of Immunologists (AAI) (1998-present); American Diabetes Association (ADA) (2002-present); Society for the Immunotherapy of Cancer (SITC) (2013-present); American Association for Cancer Research (AACR) (2016-present); Permanent Member-NIH Cell Mediated Immunity Study Section A (CMI-A) (2005-2009); The Journal of Immunology-Section Editor (2008-2012); Alliance for Cancer Gene Therapy-Scientific Advisory Council (2015-present); Cancer Immunology Research-Commissioning Deputy Editor (2016-present). Dr. Vignali received: The Robert and Janice Compton Research Grant, In Honor of Elizabeth S. Compton from the JDRF and the 2007 Faculty Mentoring Award from St. Jude Children’s Research Hospital.
Collison LW, Workman CJ, Kuo TK, Boyd K, Wang Y, Vignali K, Cross R, Sehy D, Blumberg RS and Vignali DAA. 2007. The inhibitory cytokine IL-35 contributes to regulatory T cell function. Nature. 450: 566-569.
Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ and Vignali DAA. 2013. Stability and function of regulatory T cells is maintained by a neuropilin-1:semaphorin-4a axis. Nature. 501: 252-256.
Turnis ME, Sawant DV, Szymczak-Workman A, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ and Vignali DAA. 2016. Interleukin-35 limits anti-tumor immunity. Immunity. 44: 316-329.
Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, Normolle D, Bettini M, Workman CJ and Vignali DAA. 2017. LAG-3 limits regulatory T cell proliferation and function in autoimmune diabetes. Science Immunology. 2: eaah4569.
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood J, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ and Vignali DAA. 2017. Interferon-γ drives Treg fragility to promote anti-tumor immunity. Cell. 169: 1130-1141.